Cargando…

What the Intensivists Need to Know About Critically Ill Myeloma Patients

Multiple myeloma (MM) is a hematological malignancy characterized by an increase in aberrant plasma cells in the bone marrow leading to rising monoclonal protein in serum and urine. With the introduction of novel therapies with manageable side effects, this incurable disease has evolved into a chron...

Descripción completa

Detalles Bibliográficos
Autores principales: Nair, Ranjit, Patel, Krina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121630/
http://dx.doi.org/10.1007/978-3-319-74588-6_98
_version_ 1783515244942852096
author Nair, Ranjit
Patel, Krina
author_facet Nair, Ranjit
Patel, Krina
author_sort Nair, Ranjit
collection PubMed
description Multiple myeloma (MM) is a hematological malignancy characterized by an increase in aberrant plasma cells in the bone marrow leading to rising monoclonal protein in serum and urine. With the introduction of novel therapies with manageable side effects, this incurable disease has evolved into a chronic disease with an acceptable quality of life for the majority of patients. Accordingly, management of acute complications is fundamental in reducing the morbidity and mortality in MM. MM emergencies include symptoms and signs related directly to the disease and/or to the treatment; many organs may be involved including, but not limited to, renal, cardiovascular, neurologic, hematologic, and infectious complications. This review will focus on the numerous approaches that are aimed at managing these complications.
format Online
Article
Text
id pubmed-7121630
institution National Center for Biotechnology Information
language English
publishDate 2019
record_format MEDLINE/PubMed
spelling pubmed-71216302020-04-06 What the Intensivists Need to Know About Critically Ill Myeloma Patients Nair, Ranjit Patel, Krina Oncologic Critical Care Article Multiple myeloma (MM) is a hematological malignancy characterized by an increase in aberrant plasma cells in the bone marrow leading to rising monoclonal protein in serum and urine. With the introduction of novel therapies with manageable side effects, this incurable disease has evolved into a chronic disease with an acceptable quality of life for the majority of patients. Accordingly, management of acute complications is fundamental in reducing the morbidity and mortality in MM. MM emergencies include symptoms and signs related directly to the disease and/or to the treatment; many organs may be involved including, but not limited to, renal, cardiovascular, neurologic, hematologic, and infectious complications. This review will focus on the numerous approaches that are aimed at managing these complications. 2019-07-09 /pmc/articles/PMC7121630/ http://dx.doi.org/10.1007/978-3-319-74588-6_98 Text en © Springer Nature Switzerland AG 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Nair, Ranjit
Patel, Krina
What the Intensivists Need to Know About Critically Ill Myeloma Patients
title What the Intensivists Need to Know About Critically Ill Myeloma Patients
title_full What the Intensivists Need to Know About Critically Ill Myeloma Patients
title_fullStr What the Intensivists Need to Know About Critically Ill Myeloma Patients
title_full_unstemmed What the Intensivists Need to Know About Critically Ill Myeloma Patients
title_short What the Intensivists Need to Know About Critically Ill Myeloma Patients
title_sort what the intensivists need to know about critically ill myeloma patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121630/
http://dx.doi.org/10.1007/978-3-319-74588-6_98
work_keys_str_mv AT nairranjit whattheintensivistsneedtoknowaboutcriticallyillmyelomapatients
AT patelkrina whattheintensivistsneedtoknowaboutcriticallyillmyelomapatients